Sugi Predict

Sugi Predict / Compounds / SCHEMBL946514

SCHEMBL946514

SCHEMBL946514

CCOC(=O)C1CCC(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ GLA P06280 2/20 0.38
▸ FKBP1A P62942 2/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ WNT3 P56703 1/20 0.36
▸ SFRP1 Q8N474 1/20 0.36
▸ ADRA1A P35348 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ AKR1C2 P52895 1/20 0.36
▸ ACE P12821 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL903617 1.00 MEN1 (0.39) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL862733 1.00 MEN1 (0.39) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL16584576 0.92 FKBP1A (0.41) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL15281912 0.92 FKBP1A (0.41) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL8266791 0.92 FKBP1A (0.41) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL3366889 0.87 KLK7 (0.34) MEN1KMT2AALDH1A1FKBP1ACHRM2
SCHEMBL16082361 0.87 KLK7 (0.34) MEN1KMT2AALDH1A1FKBP1ACHRM2
SCHEMBL1372911 0.87 CHRM2 (0.41) MAPTCHRM2CHRM1CHRM3WNT3
SCHEMBL713924 0.87 CHRM2 (0.41) MAPTCHRM2CHRM1CHRM3WNT3
SCHEMBL30289778 0.87 CHRM2 (0.41) MAPTCHRM2CHRM1CHRM3WNT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809024-B2 Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor ASTRAZENECA AB (SE) 2014-08-19 — — US claimed
US-20130204012-A1 Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-08 — — US claimed
WO-2013111158-A2 PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR MSN LABORATORIES LIMITED (IN) 2013-08-01 — — WO claimed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
US-20250186392-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2025-06-12 — — US disclosed
US-12167998-B2 Spiro-lactam NMDA receptor modulators and uses thereof TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) 2024-12-17 — — US disclosed
US-20240368078-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2024-11-07 — — US disclosed
WO-2023244615-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-7553861-B2 Dipeptidyl peptidase-IV inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-06-30 — — US disclosed
US-7534792-B2 e.g. 1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-methylpyrrolidine-2-carboxamide; tyrosine kinase inhibitor; anticarcinogenic, antiproliferative agent, neurodegenerative diseases; Alzheimer's disease BRISTOL-MYERS SQUIBB COMPANY (US) 2009-05-19 — — US disclosed
EP-2041138-A2 PYRROLOTRIAZINE KINASE INHIBITORS Brystol-Myers Squibb Company (US) 2009-04-01 — — EP disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 — — WO disclosed
WO-2008064218-A2 AMIDO ANTI-VIRAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-29 — — WO disclosed
CN-101168514-A Practical synthesis method for alpha-aminosuberate and alpha-amino suberic acid monoester with optical activity SHANGHAI PHARMATECH CO LTD (CN) 2008-04-30 — — CN disclosed
WO-2008005956-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-10 — — WO disclosed
US-20080009497-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 — — US disclosed
WO-2006116157-A9 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS INC (US) 2007-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186392-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A MEN1 2012/4885KMT2A 1466/4885ALDH1A1 2288/4885
US-12167998-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A MEN1 2012/4885KMT2A 1466/4885ALDH1A1 2288/4885
US-20080009497-A1 PYRROLOTRIAZINE KINASE INHIBITORS STK25, STK17A, STK35 MEN1 3067/4885KMT2A 844/4885ALDH1A1 3049/4885
US-20130204012-A1 Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor DNPEP, DPP4, PEPD MEN1 2318/4885KMT2A 2694/4885ALDH1A1 377/4885
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS MEN1 304/4885KMT2A 852/4885ALDH1A1 3667/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS MEN1 221/4885KMT2A 1189/4885ALDH1A1 1158/4885
US-20240368078-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNH2, KCNH3 MEN1 1996/4885KMT2A 391/4885ALDH1A1 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.